Biotech Values

[ghmm]

UTHR:

They reported positive results in FREEDOM-M (Monotherapy for their Oral version of Treprostinil) BUT...

http://finance.yahoo.com/news/FREEDOMM-Trial-of-Oral-prnews-1510401822.html?x=0&.v=1

http://files.shareholder.com/downloads/UTHR/815891219x0x473236/103ad2d3-af21-4725-b55a-6682029610b9/Investor%20Presentation%202011.06.06%20%28FINAL%29.pdf

The 6 minute walk distance was much lower than their target. I did a quick look at the slides and am wondering if patients didn't reach a high enough dose on the drug (though I believe the company had said in patients it appeared to be more potent than in health volunteers). Still the drug seemed much better tolerated then I thought. I think the drug gets approved eventual. Combo trial results are expected in a couple months (the previous trial just missed).